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Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)
Leukemia ( Tyrosine kinase (TK) inhibitors directed against the BCR-ABL TK domain have become the standard of treatment in patients with chronic myeloid leukemia (CML). In a proportion of patients, however, resistance to TK inhibitors may occur, which, in the case of imatinib, has been associated with point mutations within the ABL TK domain in 40-90% of instances, depending on the CML phase, the methodology of detection and the definition of resistance. 1 Mutations conferring resistance frequently occur at the ATP-binding site (P-loop) or at other sites directly affecting drug binding or conformation of the kinase (activation loop, catalytic domain). The level of resistance to individual TK inhibitors may vary from slightly reduced sensitivity to total insensitivity. In patients receiving treatment with imatinib, mutations conferring only moderately impaired sensitivity may be approached by increasing the dose, while the presence of mutations associated with a high level of resistance provides an indication for switching treatment to second generation compounds, such as dasatinib or nilotinib. 2 Point mutations reported to confer high levels of resistance to imatinib include for example, Y253F/H, E255K/V, T315I, or H396P/R. 2 Dasatinib and nilotinib were shown to be instrumental against most of these mutations, 3 but the AA position 315 (-T315I) remains problematic because none of the currently approved TK inhibitors are effective in this instance. 4 Moreover, recent data indicate that a range of specific mutations other than the T315I may occur before and during treatment with dasatinib (V299L, T315A, F317I/S/V, F317L) or nilotinib (Y253H, E255V, F359C). 5 These observations underscore the importance of monitoring patients on treatment with TK inhibitors for the presence of mutations. A number of studies in CML patients report on the occurrence of mutations in the entire BCR-ABL TK domain. Recent studies in patients treated with imatinib indicate that E250K, Y253F, E255K, T315I, M351T and F359V account for 60-70% of all mutations. Mutations located within the P-loop appear to be most frequent and are suggested to correlate with poor outcome. 6 A number of methods have been employed to detect mutant clones including, for example, PCR amplification coupled with direct sequencing of the BCR-ABL TK domain, high-performance liquid chromatography, the SEQUENOM MassARRAY system, or allele-specific oligonucleotide-PCR amplification. These techniques display different detection limits for the identification of mutant clones ranging from 0.01-30%. Detection of a mutation within the ABL TK domain does not necessarily imply impending onset of clinically resistant disease, particularly if the size of a mutant clone is small. 7 Mutant clones have been reported to disappear spontaneously which may, at least in part, be attributable to the occurrence of mutations in cells with restricted proliferative capacity. 8, 9 Qualitative methods for mutational analysis may therefore have limited potential to reliably assess the risk of clinically resistant disease, especially if mutant clones present at very low levels are detected. 8 It is currently a matter of discussion whether the detection of small mutant BCR-ABL clones, for example, below the level of 1%, is clinically useful. The clinical benefit of sensitive techniques for mutational analysis could be increased if the size of mutant clones could be monitored, to facilitate timely detection of clonally expanding mutant cells during treatment. 8 Current approaches to assessing the size of mutant clones include for example, pyrosequencing, 9 SEQUENOM MassARRAY analysis, 10 or the polymerase colony assay. 11 These techniques, however, have limitations with regard to broad application in clinical diagnosis, such as the requirement of very expensive equipment, 10 rather complex and laborious design, 11 or the apparent inability to quantify mutant clones in the range below 20%. 9 We have therefore established a relatively simple method facilitating quantitative analysis of single nucleotide polymorphisms. The technique is based on ligation-dependent competitive PCR (LD-PCR) and represents a modification of the MLPA technology. 12 The LD-PCR technique presented displays a detection limit for BCR-ABL TK mutations in a range of apparent clinical relevance, and permits accurate quantitative analysis of mutant clones. In a pilot study, we demonstrate that the technique can be readily applied to the detection and monitoring of clones exhibiting specific mutations within the BCR-ABL TK domain in patients with CML.
The panel of quantification assays presented covers 18 different mutations including all important base substitutions located in the P-loop of the tyrosine kinase domain, and other mutations known to confer a high level of resistance to imatinib, dasatinib and nilotinib ( Table 1 ). The current panel of LD-PCR assays permits detection and quantitative monitoring of the following mutations: M244V, L248V, V299L-C, V299L-T, G250E, Q252H-C, Q252H-T, Y253F, Y253H, E255K, T315A, T315I, F317C, F317I, F317L-A, F317L-G, F317V and M351T ( Table 1) .
The probes for individual LD-PCR assays including the ligation (Lig) and hybridization (Hyb) oligonucleotides were designed according to the criteria established for MLPA analysis, as specified by MRC Holland (www.mpla.com). Lig specifies the probes whose 3 0 terminal bases hybridize to the nucleotide of interest, and Hyb indicates the adjacent probe ( Figure 1 ). The Hyb probe is phosphorylated at the 5 0 end as a prerequisite for the ligation step. The Lig probes for the wild-type (WT) and the mutant (MUT) sequences display different nucleotides at their 3 0 terminal positions. Moreover, the Lig-MUT probes contain an additional 'stuffer-sequence' located between the hybridization sequence and the primer-binding site. The stuffer-sequence is a stretch of six non-homologous nucleotides which render the mutation-specific PCR product longer, and thus, readily distinguishable from the wild-type PCR product by capillary electrophoresis (Figure 1 ). The sequences of the Lig and the Hyb oligonucleotide probes were controlled for the possible formation of secondary structures under conditions close to the hybridization temperature, using a program freely available online: http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/ dna-form1.cgi.
To obtain positive controls for specific mutations in the BCR-ABL TK domain and to establish calibration curves for quantitative analysis, plasmids containing the point mutations of interest were generated. A BCR-ABL TK domain fragment of about 1 kb was amplified and cloned into a pGEMt vector (Promega, Mannheim, Germany). Presence of the wild-type BCR-ABL sequence was confirmed by direct sequencing in both directions. This plasmid served as a basis for specific mutagenesis within the ABL TK domain using the QuikChange II SiteDirected Mutagenesis Kit (Stratagene, CA, USA). Mixtures of wild-type plasmids and mutant plasmids were used to generate dilution series including the following dilution steps: 0, 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100%. Individual dilution series were analyzed in triplicates as a basis for the establishment of standard curves. An exemplary standard curve is shown in Figure 2 . The standard curves were used to convert the values measured by LD-PCR to percentages of cells displaying a specific mutation, to account for the differences between measured and true values. A statistical program specifically designed for the present study was employed for the evaluation of measurements in CML patients. Initial statistical evaluation was based on independent analysis of LD-PCR detection systems for three different mutations (T315I, E250G, Y253F). For each detection system, three dilution series d k were produced at levels x ¼ 0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9, 0.95, 0.99 and 1. For each dilution series, three LD-PCR analyses l j(k) were conducted independently and each LD-PCR assay was subjected to two independent measurements by fluorescent capillary electrophoresis a i(j(k)) . Denoting the measurements with y, the following model was applied:
is a non-linear function, the factors d k , l j(k) and a i(j(k)) are nested, and e ijk is the error term. Analysis was restricted to polynomial regression, where f(x) is a polynomial of maximal degree four. To assess the influence of factors possibly affecting quantitative measurements, we performed analysis of covariance using SAS PROC GLM (SAS Institute Inc., SAS 9.1.3 Help and Documentation, Cary, NC, USA: SAS Institute Inc., [2000] [2001] [2002] [2003] [2004] . After ensuring that neither the dilution series d k nor the fragment analysis a i(j(k)) exert significant effects, we took the average over measurements by fluorescent capillary electrophoresis and then considered the simplified model y ¼ f(x,b) þ e, where the term e contains all random errors due to dilution series and LD-PCR. Based on our analysis, the error resulting from dilution series can be regarded as negligible compared to the error derived from the LD-PCR. The computation of confidence intervals of x was performed in Matlab using polynomial regression as described. 13 Biostatistical calculation of a total of 648 data points generated for the three mutations indicated, identified the LD-PCR itself as the only statistically relevant variable affecting quantitative analysis. Based on the evaluation of this model, the standards for quantitative analysis of all other mutations were established according to a statistical design based on the remaining variable determined as relevant. Hence, for every other mutation, 36 data points were collected to establish standards for quantification.
The LD-PCR reactions were performed using the thermocycler AB-9600 (Applied Biosystems(AB), Foster City, USA). For LD-PCR, the following reaction components were mixed on ice: 0.5 ml probe mix (0.8 ml from 1 mM concentrations of each Lig-WT probe, Lig-MUT probe and Hyb probe in 200 ml TE buffer), 1.5 ml of MLPA buffer (MRC Holland, Amsterdam, The Netherlands) and 50 ng of the BCR-ABL PCR product (determined by photometric measurement). The BCR-ABL products were derived from patient specimens (see below) or from calibration plasmid samples generated by one or two rounds of PCR amplification.
14 To prevent formation of secondary structures within the target or probe sequences and self-hybridization of the probes, which might affect the efficiency of the assay, the reactions were subjected to a hot-start at 98 1C for 5 min. For specific binding of the Lig and Hyb probes, the reaction was cooled down to the appropriate hybridization temperature (Table 1) . In contrast to the original MLPA technology, the hybridization time of the LD-PCR was shortened from 16 hours to one minute. This change allowed rapid processing and accurate quantification of mutated cell clones in patient samples, while the sensitivity of detection remained unaffected. Subsequently, the reactions were placed at 54 1C for the addition of ligation reagents: 32 ml of ligation components including 3 ml Ligase-65 buffer A, 3 ml Ligase-65 buffer B, 1 ml Ligase 65 (all MRC Holland) and 25 ml water were added to the reaction. The ligase reactions were performed for 15 min at 54 1C, followed by inactivation of the enzyme for 5 min at 98 1C and cooling of the samples to 4 1C. Ten ml of this reaction were mixed with 4 ml 10 Â SALSA PCR buffer (MRC Holland) and 26 ml sterile water. After heating to 60 1C to prevent non-specific primer annealing, the reaction was supplemented with 10 ml of the PCR-mix containing 2 ml FAM-labelled SALSA PCR primers, 2 ml SALSA enzyme dilution buffer, 0.5 ml SALSA polymerase (all MRC Holland) and 5.5 ml sterile water. Subsequently, the appropriate amplification program was performed, as described. 12 The possible occurrence of false-positive LD-PCR results was controlled (and successfully excluded) by testing of multiple BCR-ABL products lacking mutations in the ABL TK domain.
Quantitative analysis was performed on the ABI PRISM 3100-Avant Genetic Analyzer (AB). The PCR product obtained from the LD-PCR reaction was diluted with sterile water at 1:50, and 1 ml of the dilution was mixed with 0.3 ml GeneScan-500 ROX Size Standard (AB) and 9 ml Hi-Di Formamide (AB). Denaturation was performed at 94 1C for 3 min, and the reaction was subsequently cooled to 4 1C. The sample was injected into a 36 cm capillary column containing the high performance (2) The ligation probe for the mutant sequence (Lig-MUT) (bn) differs from the Lig-WT probe by a nucleotide at the 3 0 terminal position complementary to a specific point mutation. This probe carries the same tag sequence (a) for the forward primer, but contains an additional stuffer sequence of six non-homologous nucleotides (c). (3) The common hybridization (Hyb) probe contains a section complementary to its target sequence directly adjacent to that of the ligation probes (d) and a tag sequence for the reverse primer (e). Upon specific hybridization to the target sequence, the probes are fused under conditions described in the text, permitting the ligation only in the presence of perfect match to the target sequence. In a subsequent step, the ligated probes are amplified competitively in a PCR reaction with a single set of primers binding to the tag sequences (a þ e). Owing to the difference in length between the WT-and MUT-derived products, the amplicons can be readily separated and quantified by fluorescent capillary electrophoresis. Results were analyzed using the ABI PRISM GeneScan Analysis software 3.7 (AB). The PCR amplicons of the WT and MUT products differed in length by 6 bp. Peak heights of the WT and the MUT products were determined, and the ratio calculated by the following formula: % MUT ¼ (peak height of MUT product/ P peak heights of MUT þ WT products) Â 100. For each mutation, calibration curves were established by preparing dilution series of quantified plasmids containing WT and MUT sequences, as indicated above.
All LD-PCR systems established were tested for the limits of detection and quantitative accuracy by using the appropriate plasmid dilution series. For several LD-PCR detection systems, the lowest dilution step analyzed (1%) could be reproducibly detected and clearly differentiated from the WT sample. However, as indicated by initial testing, reliable distinction between WT and MUT targets at levels below 5% has been difficult for some of the mutations included in the current panel, because of the presence of cross-reactivity inherent in individual detection systems. The observation of cross-reactivity was apparently related to the nucleotide composition at and near the mutant site. For example, mutations representing a G/C substitution tended to show a higher potential for non-specific binding to the target sequence than other non-matching bases. In some instances, problems associated with the target sequence could be overcome by designing LD-PCR systems targeting the opposite DNA strand, as performed for example, for the mutations Q252H-C and Q252H-T (Table 1 ). In practice, most detection systems lacking cross-reactivity actually reach a detection limit of 1%, while the assays displaying the highest levels of cross-reactivity observed only permit reliable identification of mutant cells at levels of X5%. Hence, the overall limit of detection for the mutations included in the study can be regarded as being in the range between 1-5%. The detection assays are highly reproducible, with an s.d. of ± 2%. The confidence intervals (95% CI) of quantitative analysis were calculated on the basis of serial testing of plasmid standards (see above) and were shown to be in a range of ±5%. We propose that two subsequent measurements of mutant clones in a patient, indicating an increasing or decreasing clone size, may be regarded as a true change if the confidence intervals of the measured values do not overlap. The application of this extremely stringent criterion should prevent the misinterpretation of variability inherent in the technique. According to this restriction and the confidence intervals calculated for individual LD-PCR detection systems, it is possible to consider elevations or decreases by 10% as true changes in the size of mutant clones. A computer program based on an algorithm for the calculation of confidence intervals for all LD-PCR detection systems has been established. The program permits automated quantitative assessment of mutant clones on the basis of values measured by LD-PCR. The implementation of this tool greatly facilitates the analysis of clinical specimens. The program is available upon request (Sandra.Preuner@ccri.at).
After careful standardization of all LD-PCR assays using appropriate plasmid constructs, applicability of the technique in the clinical setting was assessed in a pilot study. Peripheral blood specimens derived from 30 CML patients with suboptimal response and seven control patients with adequate response to treatment with imatinib were tested. All patients studied were initially screened for the presence of mutations in the entire TK domain by direct bidirectional sequencing of appropriate PCR products, as described. 14 The results served as a basis for subsequent quantitative analysis by LD-PCR. Seven patients with suboptimal response to imatinib revealed four different mutations including M244V, Y253H, G250E and M351T (Table 2 ). Other specimens analyzed had no evidence of mutations in the TK domain at the sensitivity level of the sequencing method. LD-PCR analysis confirmed the findings and facilitated assessment of the proportion of mutant cells in peripheral blood specimens (Table 2) . To determine the applicability of LD-PCR analysis to the monitoring of the proliferation kinetics of mutant clones, six consecutive peripheral blood samples of a CML patient carrying a M351T mutation were analyzed. In this proof of principle experiment, serial LD-PCR analysis revealed expansion of the mutant clone during the course of treatment (Figure 3 ). It should be pointed out that the LD-PCR method was not designed for broad mutational screening. The technique is appropriate for rapid search for a limited number of specific mutations of interest, and for quantitative monitoring of cell clones carrying one or more known mutations. It appears that the method presented may be particularly useful in the following clinical circumstances:
(a) In the screening for individual mutations of interest. For example, in patients resistant to imatinib, where the presence of a particular mutation (for example, the T315I), GGG-GAG  100  2  Y253H  TAC-CAC  100  3  G250E  GGG-GAG  100  4  M351T  ATG-ACG  14  5  M244V  ATG-GTG  97  6  G250E  GGG-GAG  51  7 M351T ATG-ACG 100
Displayed are the types of mutation detected by sequence analysis in seven CML patients with suboptimal response to treatment with imatinib and the relative sizes of mutant clones determined at individual time points by LD-PCR and fluorescent capillary electrophoresis. Allogeneic stem cell transplantation (SCT) with reducedintensity conditioning (RIC) has been demonstrated to be effective in achieving long-term disease-free survival with an acceptable toxicity in older patients with myelofibrosis, and patients often demonstrate reversal of marrow fibrosis and cytopenias. 1, 2 When disease relapses, patients may benefit from donor lymphocyte infusion (DLI) and achieve remission. 3 The accepted mechanism of this therapy is harnessing of the graft-versus-tumor effect (GvT); however, it may be associated with graft-versus-host disease (GVHD) and related morbidity and mortality. Here, we describe a patient with postpolycythemic myeloid metaplasia (PPMM) who relapsed after SCT with a clinical presentation of polycythemia vera (PV) and responded to DLI without demonstrating GVHD. Moreover, analysis of the JAK2-V617F mutation levels correlated with his disease course and demonstrated a 'molecular remission' after receiving DLI.
A 55-year-old man was diagnosed with PV in October 1984. At presentation, he had a hematocrit of 58%, mild leukocytosis, splenomegaly (17 cm on an ultrasound scan) and increased red cell mass by isotope dilution technique. He was treated with recurrent phlebotomy and hydroxyurea to keep his hematocrit at normal limits. Spleen size also decreased with therapy. During
